Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice

• Main Authors: Juan Jose de la Cruz (Author), Liliana Villanueva-Lizama (Author), Victor Dzul-Huchim (Author), María-Jesus R (Author), Pedro Martinez-Vega (Author), Miguel Rosado-Vallado (Author), Jaime Ortega-Lopez (Author), Claudia Ivonne Flores-Pucheta (Author), Portia Gillespie (Author), Bin Zhan (Author), Maria Elena Bottazzi (Author), Peter J. Hotez (Author), Eric Dumonteil (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A therapeutic vaccine for human Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi) is under development based on the success of vaccinating mice with DNA constructs expressing the antigens Tc24 and Tc-TSA-1. However, because DNA and nucleic acid vaccines produce less than optimal...